Drug-induced hepatitis (DIH) is one of the major complications among the treatment of patients with tuberculosis (TB); it might even be fatal. This study tries to address the recurrence of DIH with 2 anti-TB regimens. In the retrospective study from 2007 to 2010, 135 TB patients with DIH who were older than 16 years were entered to study. The patients with DIH were randomly treated with a regimen, including isoniazid, rifampin, and ethambutol, plus either ofloxacin or pyrazinamide. The patients were reviewed for occurrence of recurrent DIH. Cure and completed treatment were considered as acceptable treatment outcomes, whereas default of treatment, treatment failure, and death were considered to be unacceptable outcomes. Therefore, 135 subjects with DIH were reviewed, and 23 patients (17%) experienced recurrence of hepatitis (19 cases in the ofloxacin group and 4 cases in the pyrazinamide group). There is no significant difference in recurrence of hepatitis between these 2 groups (P 5 0.803). An acceptable outcome was observed in 95 patients (70.4%), and an unacceptable outcome was seen in 14 cases (10.3%). There was no significant difference in outcomes between these 2 regimens (P 5 0.400, odds ratio 5 1.62, 95% confidence interval, 0.524-4.98). The results of our study suggest that ofloxacin-based anti-TB regimen does not decrease the risk of recurrent DIH. Therefore, adding ofloxacin in the case of DIH is not recommended.
INTRODUCTION
Human tuberculosis (TB) has caused 1.5 million deaths around the world only in 2013. This alarming mortality rate ranks TB as a leading cause of death from treatable infectious diseases. 1 Despite of over 50 years of history of anti-TB chemotherapy, the corner stone of anti-TB treatment is a 6-month therapy with isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), and ethambutol (ETB). 2 Adherence to treatment has a pivotal role in the management of TB, where the complications of treatment make it difficult. 3 Among these, druginduced hepatitis (DIH) is one of the major obstacles of TB treatment, which can even be fatal. 4 Reduction of adherence to treatment is an important challenge in TB control programs in both developed and developing countries. 5, 6 In this case, drug hepatotoxicity can cause default of treatment and/or prolonged hospital stay.
Standard TB treatment is based on at least 3 hepatotoxic drugs, including INH, RIF, and PZA. These factors include things, such as excessive use of alcohol, older age, female sex, malnutrition, HIV, viral hepatitis, and liver diseases, that increase the risk of DIH. In our practice, a majority of patients have at least one of these risk factors. [7] [8] [9] [10] [11] This regard, monitoring with liver function tests, is recommended by American Thoracic Society in alcohol consumers, chronic hepatitis B or C, HIV-infected patients, and in those who have elevated baseline transaminase levels with an underlying liver disease. 12 Although fluoroquinolones are not recommended as first-line standard anti-TB drugs, they have been used as salvage treatment of drug-resistant TB and considered as a substitute regimen for drug intolerance. 13, 14 Previous published researches are limited in comparison between prescription of ofloxacin and other standard anti-TB drugs regarding liver injury during the course of therapy. Therefore, to assess the differences in the rate of recurrent DIH between these 2 regimens, the medical records of TB patients were examined for recurrence of drug-induced liver injury when treated with ofloxacin replacement regimen.
MATERIAL AND METHODS
The retrospective descriptive study was conducted in Masih Daneshvari hospital, a referral center for TB and lung diseases in Tehran. Throughout the 3-year duration, confirmed pulmonary TB patients who developed DIH were evaluated for recurrence of DIH. TB was confirmed by positive culture for mycobacterium TB, acidfast bacilli in sputum smear, or DNA polymerase chain reaction with clinical correlation, which is according to the World Health Organization (WHO) guideline. 15 Liver function tests were performed on all patients on the first day of hospitalization. During their hospitalization, in the case of high liver enzymes level and clinical symptoms of hepatitis, further investigation with liver ultrasound examination, serologic tests for hepatitis B and C virus infection, and HIV serology was performed.
DIH was defined as a 3-fold increase in alanine aminotransferase enzyme level in addition to clinical symptoms, including nausea, vomiting, abdominal pain, jaundice, fatigue, and weakness. Also, a 5-fold increase in liver enzymes level without clinical signs and symptoms or escalation in total bilirubin up to 2-fold was considered as DIH. In the case of liver injury, INH, RIF, and PZA were discontinued, whereas ETB was saved. Then, ofloxacin and amikacin were added to the anti-TB regimen; therefore, the patients received ETB, ofloxacin, and amikacin. 12, 16 After returning alanine aminotransferase level to normal range (up to 1.5-fold increased level accepted), RIF was initiated with one-third dose, gradually reached to full dose, and amikacin discontinued with RIF full dose. Then, INH and PZA were prescribed sequentially to reach their maximum daily dose, where in high-risk patients, ofloxacin was saved and PZA was not rechallenged. Thus, 1 group of patients received INH, RIF (and ETB) with PZA, and another group received INH, RIF (and ETB), and ofloxacin. This selection was based on the patients' underlying diseases and condition and made by clinicians.
Patients were visited biweekly until 2 months after DIH. Cure and completed treatment were considered to be acceptable treatment outcomes, whereas unacceptable outcomes included the default of treatment, treatment failure, and death. Types of TB cases (new cases, relapse, inferred in, and default of treatment) and TB classification (pulmonary and extrapulmonary TB) were considered based on the WHO definitions. 15 The patients without complete demographic, clinical, laboratory, and treatment outcome were excluded from the study. Statistical analysis was performed using SPSS version 16 
RESULTS

Demographics
A total 135 patients were enrolled with DIH, where 67 subjects (49.6%) were male. Patients were between the ages of 16 and 86 years with mean 6 SD (53 6 21). The demographic information is shown in Table 1 .
Clinical characteristics
Type of TB cases and TB classification were addressed according to the WHO definitions 15 (Table 2) . HIV infections were examined in 129 cases (95.5%), of these, 7 (12.6%) were positive. The most underlying diseases were diabetes mellitus, hypertension, and hepatitis C virus infection, respectively. In total, 71 patients (52.6%) had underlying diseases (Table 2 ). There is no significant difference between 2 groups of drug regimen in TB classification, type of TB, underlying disease conditions, HIV, and viral hepatitis status (Table 2) .
Drug hepatitis
Twenty-three of total (135) DIH patients (17%) experienced recurrent drug hepatitis, 19 cases with ofloxacin regimen (ofloxacin plus INH, RIF, and ETB), and 4 cases with PZA (PZA plus INH, RIF, and ETB). Statistical analysis with x 2 did not show significant difference between 2 groups in recurrence of DIH (P 5 0.803).
Treatment outcome
Treatment outcomes are described in Table 2 . Comparison of the treatment outcome between ofloxacin and PZA regimens demonstrated that 95 patients (87%) in the ofloxacin group and 21 patients (80%) in the PZA group had an acceptable outcome. There was no significant difference between 2 groups in acceptable outcome (P 5 0.400, odds ratio 5 1.62, 95% confidence interval 0.52-4.98) ( Table 2) .
Total DIH patients (135) and recurrent group did not show significant difference in sex, age groups, nationality, smoking, opium consumption, underlying diseases, and viral hepatitis (Table 3) .
DISCUSSION
TB is still one of the most threatening infectious diseases in the world, and its standard treatment is along with complications such as DIH, which can decrease patient adherence to treatment. 15, 17 In undeveloped countries, higher incidence of TB may cause a higher burden of DIH. Moreover, the incidence of DIH because of anti-TB drugs is higher in these countries. 18 Therefore, this issue is not only important for clinical practitioners to manage the patients' illness, but also the burden of this complication should be considered within the health service policy and management.
We did not match the cases and control for study as a clinical trial, but as shown in Tables 1 and 2 , demographic and clinical characteristics did not illustrate significant differences between groups treated with ofloxacin regimen or PZA. Thus, these 2 groups are proportionate, and we can study the effect of drug regimen in recurrence of DIH in this survey. According to these results, smoking and use of illegal drugs that are considered risk factors for hepatotoxicity 19 did not show significant difference between DIH and recurrent DIH groups (Table 3) .
The results of previous studies about the effect of PZA in addition to standard triple-drug regimen (INH, RIF, and ETB) on DIH have been incompatible. According to the study by Makhlouf et al, adding PZA did not change the risk of DIH. 20 This result also has been supported by other studies. 8, 18, 21 But in other studies, 5, 15, 22 DIH dramatically rises with adding PZA. Therefore, it seems the effects of 1 drug in induced-liver injury in various contexts may be very different. Also, we should consider that demographic and clinical characteristics should be matched for these studies. For example, it is well known that underlying diseases, particularly viral hepatitis, affect the liver function. 23, 24 However, in this study, a significant difference in the underlying disease (comorbidity) between recurrent DIH and DIH groups was not seen (Table 3) . Also, the study did not report the effect of age and sex in recurrence of liver injury. Another study by Devarbhavi et al did not show significant difference by age and sex in anti-TB drug-induced hepatotoxicity. The lack of significant difference in recurrent hepatitis between these 2 groups suggests that alternative therapy with ofloxacin in all cases is not required. However, despite less medication side effects and better drug tolerance of ofloxacin, this drug should be saved for patients with some risk factors, such as excessive use of alcohol, older age, female sex, malnutrition, HIV infection, underlying liver diseases, and viral hepatitis, considering this drug belongs to second line of anti-TB treatment and it is applicable in multidrug resistant and extensively drug-resistant TB patients. 26 This study is limited in patients' selections, which were initially chosen in both groups by clinical judgment. But, because the significant demographic and clinical characteristics' difference was not seen between these 2 groups, this issue should not affect the conclusion. Also, the number of cases in recurrence of DIH is limited, especially in PZA group. Considering that this study is the first comparison of 2 regimen groups including PZA or ofloxacin, the findings of this study should be validated in a cohort with more patients, as in a double-blind clinical trial. 
